Washington University in St. Louis School of Medicine researchers have used next-generation sequencing to identify mutations in HER2 that are missed by standard screening tests. Based on the findings, the researchers are now recruiting patients with breast cancer expressing the mutations for a Phase II trial of Puma's HER2-targeting compound, neratinib.